Cargando…

Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies

Aim: Systemic pharmacotherapies have limitation due to blood-labyrinth barrier, so local delivery via the round window membrane opens a path for effective treatment. Multifunctional nanoparticle (NP)-mediated cell specific drug delivery may enhance efficacy and reduce side effects. Different NPs wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Glueckert, Rudolf, Pritz, Christian O., Roy, Soumen, Dudas, Jozsef, Schrott-Fischer, Anneliese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436893/
https://www.ncbi.nlm.nih.gov/pubmed/26042029
http://dx.doi.org/10.3389/fnagi.2015.00071
_version_ 1782372154562576384
author Glueckert, Rudolf
Pritz, Christian O.
Roy, Soumen
Dudas, Jozsef
Schrott-Fischer, Anneliese
author_facet Glueckert, Rudolf
Pritz, Christian O.
Roy, Soumen
Dudas, Jozsef
Schrott-Fischer, Anneliese
author_sort Glueckert, Rudolf
collection PubMed
description Aim: Systemic pharmacotherapies have limitation due to blood-labyrinth barrier, so local delivery via the round window membrane opens a path for effective treatment. Multifunctional nanoparticle (NP)-mediated cell specific drug delivery may enhance efficacy and reduce side effects. Different NPs with ligands to target TrkB receptor were tested. Distribution, uptake mechanisms, trafficking, and bioefficacy of drug release of rolipram loaded NPs were evaluated. Methods: We tested lipid based nanocapsules (LNCs), Quantum Dot, silica NPs with surface modification by peptides mimicking TrkB or TrkB activating antibodies. Bioefficacy of drug release was tested with rolipram loaded LNCs to prevent cisplatin-induced apoptosis. We established different cell culture models with SH-SY-5Y and inner ear derived cell lines and used neonatal and adult mouse explants. Uptake and trafficking was evaluated with FACS and confocal as well as transmission electron microscopy. Results: Plain NPs show some selectivity in uptake related to the in vitro system properties, carrier material, and NP size. Some peptide ligands provide enhanced targeted uptake to neuronal cells but failed to show this in cell cultures. Agonistic antibodies linked to silica NPs showed TrkB activation and enhanced binding to inner ear derived cells. Rolipram loaded LNCs proved as effective carriers to prevent cisplatin-induced apoptosis. Discussion: Most NPs with targeting ligands showed limited effects to enhance uptake. NP aggregation and unspecific binding may change uptake mechanisms and impair endocytosis by an overload of NPs. This may affect survival signaling. NPs with antibodies activate survival signaling and show effective binding to TrkB positive cells but needs further optimization for specific internalization. Bioefficiacy of rolipram release confirms LNCs as encouraging vectors for drug delivery of lipophilic agents to the inner ear with ideal release characteristics independent of endocytosis.
format Online
Article
Text
id pubmed-4436893
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44368932015-06-03 Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies Glueckert, Rudolf Pritz, Christian O. Roy, Soumen Dudas, Jozsef Schrott-Fischer, Anneliese Front Aging Neurosci Neuroscience Aim: Systemic pharmacotherapies have limitation due to blood-labyrinth barrier, so local delivery via the round window membrane opens a path for effective treatment. Multifunctional nanoparticle (NP)-mediated cell specific drug delivery may enhance efficacy and reduce side effects. Different NPs with ligands to target TrkB receptor were tested. Distribution, uptake mechanisms, trafficking, and bioefficacy of drug release of rolipram loaded NPs were evaluated. Methods: We tested lipid based nanocapsules (LNCs), Quantum Dot, silica NPs with surface modification by peptides mimicking TrkB or TrkB activating antibodies. Bioefficacy of drug release was tested with rolipram loaded LNCs to prevent cisplatin-induced apoptosis. We established different cell culture models with SH-SY-5Y and inner ear derived cell lines and used neonatal and adult mouse explants. Uptake and trafficking was evaluated with FACS and confocal as well as transmission electron microscopy. Results: Plain NPs show some selectivity in uptake related to the in vitro system properties, carrier material, and NP size. Some peptide ligands provide enhanced targeted uptake to neuronal cells but failed to show this in cell cultures. Agonistic antibodies linked to silica NPs showed TrkB activation and enhanced binding to inner ear derived cells. Rolipram loaded LNCs proved as effective carriers to prevent cisplatin-induced apoptosis. Discussion: Most NPs with targeting ligands showed limited effects to enhance uptake. NP aggregation and unspecific binding may change uptake mechanisms and impair endocytosis by an overload of NPs. This may affect survival signaling. NPs with antibodies activate survival signaling and show effective binding to TrkB positive cells but needs further optimization for specific internalization. Bioefficiacy of rolipram release confirms LNCs as encouraging vectors for drug delivery of lipophilic agents to the inner ear with ideal release characteristics independent of endocytosis. Frontiers Media S.A. 2015-05-19 /pmc/articles/PMC4436893/ /pubmed/26042029 http://dx.doi.org/10.3389/fnagi.2015.00071 Text en Copyright © 2015 Glueckert, Pritz, Roy, Dudas and Schrott-Fischer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Glueckert, Rudolf
Pritz, Christian O.
Roy, Soumen
Dudas, Jozsef
Schrott-Fischer, Anneliese
Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies
title Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies
title_full Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies
title_fullStr Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies
title_full_unstemmed Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies
title_short Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies
title_sort nanoparticle mediated drug delivery of rolipram to tyrosine kinase b positive cells in the inner ear with targeting peptides and agonistic antibodies
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436893/
https://www.ncbi.nlm.nih.gov/pubmed/26042029
http://dx.doi.org/10.3389/fnagi.2015.00071
work_keys_str_mv AT glueckertrudolf nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT pritzchristiano nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT roysoumen nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT dudasjozsef nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies
AT schrottfischeranneliese nanoparticlemediateddrugdeliveryofrolipramtotyrosinekinasebpositivecellsintheinnerearwithtargetingpeptidesandagonisticantibodies